The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Human IgG4: a structural perspective
Open accessAbstract
Summary: IgG4, the least represented human IgG subclass in serum, is an intriguing antibody with unique biological properties, such as the ability to undergo Fab‐arm exchange and limit immune complex formation. The lack of effector functions, such as antibody‐dependent cell‐mediated cytotoxicity and complement‐dependent cytotoxicity, is desirable for therapeutic purposes. IgG4 plays a protective role in allergy by acting as a blocking antibody, and inhibiting mast cell degranulation, but a deleterious role in malignant melanoma, by impeding IgG1‐mediated anti‐tumor immunity. These findings highlight the importance of understanding the interaction between IgG4 and Fcγ receptors. Despite a wealth of structural information for the IgG1 subclass, including complexes with Fcγ receptors, and structures for intact antibodies, high‐resolution crystal structures were not reported for IgG4‐Fc until recently. Here, we highlight some of the biological properties of human IgG4, and review the recent crystal structures of IgG4‐Fc. We discuss the unexpected conformations adopted by functionally important Cγ2 domain loops, and speculate about potential implications for the interaction between IgG4 and FcγRs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Malhotra, R., Wormald, M. R., Rudd, P. M., Fischer, P. B., Dwek, R. A., & Sim, R. B. (1995) · Nature Medicine · doi:10.1038/nm0395-237 · Cited by 786
Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770
Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex
Martin, W. L., West, A. P., Gan, L., & Bjorkman, P. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00230-1 · Cited by 391
Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function
James, L. C., Keeble, A. H., Khan, Z., Rhodes, D. A., & Trowsdale, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609174104 · Cited by 386 · cited 2×
“2D) provides a mechanism for intracellular antibody recognition in antiviral responses (61, 77, 87).”
BackgroundStructure and function relationships in IgA
Woof, J. M., & Russell, M. W. (2011) · Mucosal Immunology · doi:10.1038/mi.2011.39 · Cited by 367
Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
Brennan, F. R., Morton, L. D., Spindeldreher, S., Kiessling, A., Allenspach, R., Hey, A., Müller, P., Frings, W., & Sims, J. (2010) · mAbs · doi:10.4161/mabs.2.3.11782 · Cited by 250
Crispin, M., Yu, X., & Bowden, T. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310657110 · Cited by 89
In-depth analysis of subclass-specific conformational preferences of IgG antibodies
Tian, X., Vestergaard, B., Thorolfsson, M., Yang, Z., Rasmussen, H. B., & Langkilde, A. E. (2015) · IUCrJ · doi:10.1107/s205225251402209x · Cited by 78 · cited 2×
“The disrupted proline sandwich could contribute to the lower affinity of IgG4 for particular FccRs, compared with IgG1 (98), but lower affinity could also be attributed to other determinants, such as substitution of the lower hinge residue Leu234 in IgG1, to Phe234 in IgG4 (21) and the overall disposition of the Fabs…”
Background
Cited by
Pathophysiology of Eosinophilic Esophagitis
O’Shea, K. M., Aceves, S. S., Dellon, E. S., Gupta, S. K., Spergel, J. M., Furuta, G. T., & Rothenberg, M. E. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.06.065 · Cited by 502
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
Zhang, T., Song, X., Xu, L., Ma, J., Zhang, Y., Gong, W., Zhang, Y., Zhou, X., Wang, Z., Wang, Y., et al. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2160-x · Cited by 290
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2300 · Cited by 244
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
Tietz, J., Gunde, T., Warmuth, S., Weinert, C., Brock, M., Simonin, A., Hess, C., Johansson, M., Spiga, F., Muntwiler, S., et al. (2024) · JID Innovations · doi:10.1016/j.xjidi.2024.100258 · Cited by 16
Metadata
- Authors
- Davies, A. M., & Sutton, B. J.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2015-10-26
- Volume
- 268
- Issue
- 1
- Pages
- 139-159
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W1895658925
- Cited by
- 170
- References
- 13
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.